...
Summer 2018 | Live Blog | Management of Eyelid Malignancies
June 29, 2018

Day 2 of the SDPA Summer Conference ended with an illuminating lecture on eyelid malignancies by Dr. Michael Yen, an oculoplastic surgeon. The most common eyelid malignancy is basal cell cancer representing 95% of eyelid malignancies. Suspicious characteristics for eyelid malignancies include growth, lid notching, ulceration, telangiectasias and deepening pigmentation. Madarosis, or loss of eyelashes,

...
Summer 2018 | Live Blog | Orocutaneous Disease: Review and Update

Dr. John Wright, an oral pathologist, presented an illuminating lecture on orocutaneous disease at the SDPA Annual Summer Conference. Dr. Wright began his talk with viral presentations of disease focusing on herpes simplex virus (HSV). Herpes simplex is a systemic virus which presents as a vesiculobullous disease. With primary herpes outbreak, it often presents panorally

...
Summer 2018 | Live Blog | Product Theater | Are Your Topical Patients Systemic Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis

The second product theater on day 2 of the SDPA Annual Summer Conference presented by Robert Casquejo, PA-C discussed Otezla as a treatment for adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy and systemic therapy. Otezla is an oral medication that inhibits phosphodiesterase 4

...
Summer 2018 | Live Blog | Product Theater | Innovations in Dermatology

The first product theater on day 2 of the SDPA Annual Summer Conference was presented by Dr. Neal Bhatia and featured the use of Onexton and Retin-A Micro for the treatment of acne. Acne vulgaris is an inflammatory pilosebaceous disease that affects greater than 80% adolescents, up to 12% women, and can persist after the

...
Summer 2018 | Live Blog | Product Theater | More Than Skin Deep with Cosentyx (secukinumab): Proven Effective for Psoriatic Arthritis
June 28, 2018

Andrea Nguyen, MS, PA-C presented the second product theater on the first day of the SDPA Annual Summer Conference. She discussed Cosentyx, the first and only fully human Il-17A antagonist approved for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. Cosentyx is also indicated for the treatment of ankylosing spondylitis. Ms. Nguyen

...
Summer 2018 | Live Blog | Comorbidities in Rosacea and Acne: Fact or Fiction?

Gina Fragione, MPAS, PA-C presented a lecture on Comorbidities in Rosacea and Acne: Fact or Fiction at the SDPA Annual Summer Conference. She began by discussing the pathophysiology of rosacea as primarily an inflammatory disorder consisting of a dysregulation of innate an adaptive immune system, and that it shares a common general pathophysiology with reported